Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.

导出 OA

翻译打印收藏纠错

作者： Guy,Cohen ^[1] ; Pawornrath,Jungsomsri ^[1] ; Jirath,Sangwongwanich ^[1] ; Kriangkrai,Tawinprai ^[2] ; Taweegrit,Siripongboonsitti ^[2] ; Thachanun,Porntharukchareon ^[2] ; Kasiruck,Wittayasak ^[3] ; Nawarat,Thonwirak ^[3] ; Kamonwan,Soonklang ^[3] ; Gaidganok,Sornsamdang ^[4] ; Chirayu,Auewarakul ^[3] ; Nithi,Mahanonda ^[5]

作者单位： Department of General Practice and Family Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand. ^[1] Department of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand. ^[2] Center of Learning and Research in Celebration of HRH Princess Chulabhorn's 60th Birthday Anniversary, Chulabhorn Royal Academy, Bangkok, Thailand. ^[3] Central Laboratory Center, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok, Thailand. ^[4] Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand. ^[5]

关键词 AZD1222 COVID-19 ChAdox1 nCov-19 CoronaVac heterologous prime-boost immunogenicity vaccine combination

主题词成年人(Adult);抗体, 病毒(Antibodies, Viral);人类(Humans);免疫接种, 加强(Immunization, Secondary);疾病大流行(Pandemics);接种(Vaccination)

DOI 10.1080/21645515.2022.2052525

PMID 35323079

发布时间 2022-10-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交